

Charles L Shapiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5997585/publications.pdf>

Version: 2024-02-01

59
papers

4,164
citations

257450

24
h-index

182427

51
g-index

61
all docs

61
docs citations

61
times ranked

6463
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic comorbid conditions among adult cancer survivors in the United States: Results from the National Health Interview Survey, 2002â€”2018. <i>Cancer</i> , 2022, 128, 828-838.	4.1	27
2	Abstract PO-140: Unsupervised clustering and data modeling reveals molecular signatures linked a distinct African American enriched cluster with higher probability of death in triple negative breast cancer. , 2022, , .		0
3	Self-reported Transportation Barriers to Health Care Among US Cancer Survivors. <i>JAMA Oncology</i> , 2022, 8, 775.	7.1	25
4	Self-reported well-being of cancer survivor (CS)-caregivers: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS).. <i>Journal of Clinical Oncology</i> , 2022, 40, e22022-e22022.	1.6	0
5	Real-world clinical outcomes in patients with local/regional HER2-low breast cancer: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	1.6	4
6	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
7	Bone-modifying Agents (BMAs) in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e618-e630.	2.4	9
8	Quality Care in Survivorship: Lessons Learned From the ASCO Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2021, 17, e1170-e1180.	2.9	3
9	Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 495-501.	2.5	34
10	Management of osteoporosis in women with breast cancer. <i>Breast Cancer Management</i> , 2020, 9, .	0.2	4
11	Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments. <i>Cancers</i> , 2020, 12, 3094.	3.7	24
12	Cancer survivors with multiple chronic conditions: A rising challengeâ€”Trend analysis from National Health Interview Survey.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24089-e24089.	1.6	3
13	Gender disparity on cigarette smoking among cancer survivors: Results from the National Health Interview Survey.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24040-e24040.	1.6	0
14	Results of a phase Ib study investigating durvalumab in combination with eribulin in patients with metastatic HER2-negative breast cancer and recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15120-e15120.	1.6	0
15	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2270-2290.	1.6	224
16	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 603-606.	2.5	4
17	De-escalation yes, but not at the expense of efficacy: in defense of better treatment. <i>Npj Breast Cancer</i> , 2019, 5, 25.	5.2	3
18	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2916-2946.	1.6	127

#	ARTICLE	IF	CITATIONS
19	Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008777.	2.6	22
20	Central nervous system metastases in triple-negative breast cancer: A step in the right direction. <i>Breast Journal</i> , 2019, 25, 361-362.	1.0	0
21	A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1109-TPS1109.	1.6	0
22	Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience. <i>Supportive Care in Cancer</i> , 2018, 26, 197-202.	2.2	8
23	Osteoporosis and musculoskeletal complications related to therapy of breast cancer. <i>Gland Surgery</i> , 2018, 7, 411-423.	1.1	19
24	Reply to L. Kennedy et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1052-1053.	1.6	2
25	Cancer Survivorship. <i>New England Journal of Medicine</i> , 2018, 379, 2438-2450.	27.0	382
26	Comparison of weight loss among early stage breast cancer patients post treatment: Nutrition education in combination with weight loss acupuncture vs. nutrition education alone.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12594-e12594.	1.6	1
27	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1103-TPS1103.	1.6	1
28	A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3116-TPS3116.	1.6	3
29	Zoledronic Acid Dosing Interval for Metastatic Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1478.	7.4	2
30	Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 48.	7.4	253
31	Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?. <i>Lancet Oncology</i> , The, 2017, 18, e445-e456.	10.7	135
32	Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3949-3955.	1.6	57
33	ReCAP: ASCO Core Curriculum for Cancer Survivorship Education. <i>Journal of Oncology Practice</i> , 2016, 12, 145-145.	2.5	61
34	Integrin-linked kinase as a novel molecular switch of the IL-6-NF- κ B signaling loop in breast cancer. <i>Carcinogenesis</i> , 2016, 37, 430-442.	2.8	18
35	Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors. <i>JAMA Oncology</i> , 2016, 2, 1401.	7.1	21
36	Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement. <i>Journal of Oncology Practice</i> , 2016, 12, e828-e838.	2.5	102

#	ARTICLE	IF	CITATIONS
37	Digitizing the cancer care continuum: Electronic, shareable survivorship care plans.. Journal of Clinical Oncology, 2016, 34, 10101-10101.	1.6	0
38	Assuring Quality Cancer Survivorship Care: We've Only Just Begun. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e583-e591.	3.8	31
39	Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating β -Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia, 2015, 17, 497-508.	5.3	38
40	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
41	Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials. Oncologist, 2015, 20, 337-343.	3.7	43
42	CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.. Journal of Clinical Oncology, 2015, 33, 9501-9501.	1.6	16
43	Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget, 2015, 6, 6373-6385.	1.8	42
44	Treatment-Related Mortality With Everolimus in Cancer Patients. Oncologist, 2014, 19, 661-668.	3.7	12
45	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). Journal of Clinical Oncology, 2014, 32, 2311-2317.	1.6	70
46	Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options. PLoS ONE, 2014, 9, e88525.	2.5	79
47	Bone Health in Adult Cancer Survivorship. Journal of Clinical Oncology, 2012, 30, 3665-3674.	1.6	101
48	NCCN Task Force Report: Bone Health in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-32.	4.9	163
49	Aromatase Inhibitor-Associated Bone Loss. Drugs, 2008, 68, 2591-2600.	10.9	22
50	Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology, 2003, 30, 763-775.	2.2	125
51	Side Effects of Adjuvant Treatment of Breast Cancer. New England Journal of Medicine, 2001, 344, 1997-2008.	27.0	596
52	Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2001, 19, 3306-3311.	1.6	417
53	Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin's Disease: A Case-Control Study. Breast Journal, 2001, 7, 46-52.	1.0	30
54	Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer, 2001, 91, 17-24.	4.1	44

#	ARTICLE	IF	CITATIONS
55	Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma. Journal of Clinical Oncology, 1999, 17, 2541-2541.	1.6	124
56	The quality of care for treatment of early stage breast carcinoma. , 1998, 83, 302-309.		69
57	The quality of care for treatment of early stage breast carcinoma. Cancer, 1998, 83, 302-309.	4.1	2
58	Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer, 1991, 68, 699-705.	4.1	23
59	Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial. Cancer, 1976, 37, 1669-1672.	4.1	2